Sunovion Pharmaceuticals Inc. Presents Data at CHEST 2013 from a One-year, Large Simple Safety Study of BROVANA® (arformoterol tartrate) Inhalation Solution
Published: Oct 29, 2013
Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a one-year, non-inferiority clinical trial, which showed that patients with moderate to severe chronic obstructive pulmonary disease (COPD) treated with BROVANA® (arformoterol tartrate) Inhalation Solution experienced no increased risk of serious respiratory events, including respiratory death or COPD exacerbation-related hospitalizations, irrespective of smoking status, age or disease severity.
Help employers find you! Check out all the jobs and post your resume.